Stimulation of TNF-α Release by Fungal Cell Wall Polysaccharides

Juraj Majtán[a], Grigorij Kogan[b,*], Elena Kováčová[c], Katarína Bíliková[a,d], and Jozef Šimúth[a]

[a] Institute of Molecular Biology, Slovak Academy of Sciences, Dúbravská cesta 21, 84551 Bratislava, Slovakia
[b] Institute of Chemistry, Center of Excellence CEDEBIPO, Slovak Academy of Sciences, Dúbravská cesta 9, 84538 Bratislava, Slovakia. Fax: +421-2-59410222. E-mail: grigorij.kogan@savba.sk
[c] Institute of Virology, Slovak Academy of Sciences, Dúbravská cesta 9, 84245 Bratislava, Slovakia
[d] Max-Planck-Institute for Molecular Genetics, Department of Vertebrate Genomics, Ihnestrasse 63–73, D-14195 Berlin, Germany

* Author for correspondence and reprint requests

Carboxymethylated derivatives were prepared from the (1→3)-β-D-glucan isolated from the cell wall of baker's yeast *Saccharomyces cerevisiae* and from the chitin-glucan complex of the mycelium of the industrial filamentous fungus *Aspergillus niger*. The polysaccharides were applied to peritoneal mouse macrophages and after a 2-h incubation the release of TNF-α by the stimulated macrophages was measured using an enzyme-linked immunosorbent assay. As the third polysaccharide stimulant, a water-soluble derivative of chitin was assayed and the observed cytokine release was compared with the control experiment. In three concentrations of the polysaccharides applied, carboxymethyl glucan revealed a dramatic increase in the TNF-α release, while addition of carboxymethyl chitin-glucan resulted only in a moderate enhancement, and carboxymethyl chitin was inactive. The results indicate that fungal polysaccharides, especially (1→3)-β-D-glucan, are potent macrophage stimulators and activators of TNF-α release, which implies their potential application in antitumor therapy.

Keywords: Tumor Necrosis Factor-α, Glucan, Chitin

Introduction

Fungal cell walls consist predominantly of polysaccharides (up to 90%), the most abundant of which is β-D-glucan (50–60% of all cell wall polysaccharides), which plays the role of a skeletal carcass defining rigidity and stability of the cell and its morphological shape (Bartnicki-Garcia, 1968; Farkaš, 1979). Glucans having a backbone built of (1→3)-β-glycosidically linked D-glucose units with variable (1→6)-β-D-glucosyl branching have been isolated from various fungal, bacterial and algal sources and in the recent decades increased attention has been paid to these compounds due to their ability to act as non-specific modulators of the immune system (Williams, 1997; Kogan, 2000). Glucans belong to the class of drugs known as biological response modifiers (Bohn and BeMiller, 1995) and numerous studies have shown that (1→3)-β-D-glucans enhance the functional status of macrophages and neutrophils (Williams *et al.*, 1996), modify immunosuppression (Browder *et al.*, 1990), increase resistance to infections by Gram-negative bacteria (Pretus *et al.*, 1991), as well as exert antitumor activity (Sherwood *et al.*, 1986, 1987).

In our previous work we have reported on antibacterial (Kogan *et al.*, 1989), antimutagenic (Čipák *et al.*, 2001), antioxidant (Babincová *et al.*, 1999; Slameňová *et al.*, 2003, Kogan *et al.*, 2005), and antitumor activities (Kogan *et al.*, 2002; Khalikova *et al.*, 2005) of the prepared water-soluble derivatives of (1→3)-β-D-glucan isolated from the cell walls of baker's yeast *Saccharomyces cerevisiae*. Now we have demonstrated that at least some of its immunomodulatory activities could be explained by an increased release of specific cytokines from the activated immunocompetent cells, *e.g.*, macrophages. At the same time, we compared its activity with that of the carboxymethylated derivative of the chitin-glucan complex from the mycelium of *Aspergillus niger*, in which β-D-glucan constitutes about 80%, and with carboxymethyl chitin (CM-C), the second polysaccharide component of the chitin-glucan complex.

Materials and Methods

Preparation of the polysaccharides

The water-insoluble $(1{\rightarrow}3)$-β-D-glucan was isolated from the commercial baker's yeast biomass purchased from Slovlik (Trenčín, Slovakia). Yeast cells were treated with 6% NaOH at 60 °C followed by 4% phosphoric acid extraction at room temperature as previously described (Kogan *et al.*, 1988). After the removal of all soluble material, β-D-glucan was left as the insoluble residue. Solubilization of the insoluble glucan was performed by means of carboxymethylation with monochloroacetic acid and aqueous NaOH in isopropyl alcohol as previously described (Machová *et al.*, 1995). The degree of carboxymethylation determined by potentiometric titration was 0.56, and the molecular mass established by HPLC was 346,000. The analyses of the prepared carboxymethyl glucan (CM-G) were performed as previously described (Machová *et al.*, 1995).

The crude chitin-glucan complex was prepared from the mycelium of the industrial strain of the filamentous fungus *Aspergillus niger* used for the commercial production of citric acid (Biopo, Leopoldov, Slovakia). Isolation, carboxymethylation and characterization of molecular parameters of the prepared carboxymethyl chitin-glucan (CM-CG) were carried out as previously reported (Machová *et al.*, 1999). The degree of carboxymethylation was established to be 0.43 by potentiometric titration, the molecular mass of the used fraction of CM-CG was ca. 60,000, and the content of chitin in the complex determined by means of ^{13}C NMR spectroscopy was ca. 14%.

The sample of chitin was purchased from Primex ehf (Siglufjordur, Iceland) and carboxymethylated using the conditions similar to those applied for carboxymethylation of the chitin-glucan complex (Machová *et al.*, 1999). The degree of carboxymethylation determined by potentiometric titration was 0.35 and the molecular mass was 150,000 as established using HPLC in the previously reported conditions (Machová *et al.*, 1999).

Animals

Male ICR mice aged 8–12 weeks were obtained from the breeding facility of the Institute of Experimental Pharmacology, Slovak Academy of Sciences (Dobrá voda, Slovakia). All animals were housed in microisolator cages in a temperature-controlled room. Food and water were provided *ad libitum*. All animal experiments were conducted according to the ethical guidelines issued by the Institute of Virology, Slovak Academy of Sciences.

Cell cultures and their activation

Peritoneal mouse macrophages were prepared according to Park and Rikihisha (1991) by means of elicitation using intraperitoneal injection of 2 ml sterile 5% thioglycolate broth (Difco Laboratories, Detroit, MI). Upon 5 d, the mice were sacrificed by applying diethyl ether and peritoneal exudates cells were collected by lavage. Cells were washed by centrifugation, resuspended [5×10^6 cells in 0.5 ml RPMI 1640 medium containing L-glutamine (PAA Laboratories GmbH, Pasching, Austria) supplemented with 10% heat-inactivated fetal bovine serum (FCS, Gibco-BRL, Life Technologies, Eggenstein, Germany)], and placed into every well of 24-well plates (Sarstedt AG & Co., Nümbrecht, Germany). Upon 2 h incubation at 37 °C in a humidified atmosphere of 5% carbon dioxide, non-adherent cells were removed by rinsing and subsequently 0.5 ml of complete RPMI 1640 medium (containing 10% FCS) supplemented with the tested polysaccharide stimulants was added to each well. After the cultivation period, the supernatants were collected and stored at − 80 °C.

Enzyme-linked immunosorbent assay (ELISA)

The content of TNF-α was determined in the cell culture supernatants collected after 3, 6, and 24 h of cultivation using an ELISA kit (DUO Set, R & D Systems, Minneapolis, MN) according to the manufacturer's instructions. A recombinant mouse TNF-α was used as reference. All assays were carried out in triplicate.

Application of the polysaccharides

Solutions of CM-G, CM-CG, and CM-C were prepared in 12.5, 25, and 50 μg/ml concentrations in complete RPMI 1640 medium and rendered sterile by filtration through a 0.22 μm membrane (Millipore, Bedford, MA).

Statistical analysis

The results are presented as mean ± standard deviation (SD). All data were statistically analyzed by a one-way analysis of variance ANOVA

and a Bonferroni test to determine whether there were differences within the groups. *P* values smaller than 0.01 were considered to be significant. The analyses were performed using Origin-Pro 7.5 software (OriginLab Corporation, Northampton, MA).

Results and Discussion

Immunomodulatory substances can be subdivided into two groups basing on their source and type of interaction with the immune system. One group contains mammalian cell products (mainly proteins) that selectively augment activities of specific cells of the lymphohematopoietic system. Another group consists of the compounds isolated from microorganisms or microbial culture fluids. The latter type of immunomodulators, also known as biological response modifiers (BRMs), usually non-specifically potentiate the host immune system by interacting with its multiple components involving innate and adaptive mechanisms. (1→3)-β-D-Glucans are probably the most extensively studied BRMs (Bohn and BeMiller, 1995; Williams, 1997; Kogan, 2000) and some of them have been used clinically in cancer therapy in Japan (Maeda *et al.*, 1988; Sakagami *et al.*, 1988) and have been involved in preclinical trials of antiseptic effect in trauma and surgical patients (Browder *et al.*, 1990; Babineau *et al.*, 1994).

Recently obtained data strongly support the assumption that (1→3)-β-D-glucans mediate their protective and immunopotentiating effect by binding to specific sites (receptors) on monocytes/macrophages and granulocytes triggering a cascade of immunological events. Among the elicited effects are: bone marrow colony stimulating activity leading to augmented production of monocytes and granulocytes, increased antibody titers, boosted cytokine release (including IL-1, IL-2, IL-6, and TNF-α), prostaglandin E$_2$ production, activation of alternative complement pathway, and release of lysosomal enzymes (Thornton *et al.*, 1996; Vetvicka *et al.*, 1996). In support of this concept, Czop and Austen (1985) have reported the observation of (1→3)-β-D-glucan receptors on human monocytes, Goldman (1988) has reported the presence of (1→3)-β-D-glucan receptor on P388D1 cells, a mouse macrophage-like tumor cell line, and Williams *et al.* (1986) have reported a (1→3)-β-D-glucan receptor on human polymorphonuclear lymphocytes. All these early studies were carried out using particulate, water-insoluble β-D-glucans and the researchers did not elucidate the nature of the receptors, which limited the *in vivo* significance of these studies. On the other hand, recent in-depth investigations performed with different water-soluble derivatives of (1→3)-β-D-glucans and their low-molecular-weight fragments corroborated the fact that β-D-glucan receptors belong to the class of pattern recognition receptors (PRR), by which the innate immune system recognizes conserved microbial structures called pathogen-associated molecular patterns (PAMPs), which include lipoteichoic acid for Gram-positive bacteria, lipopolysaccharide (LPS) for Gram-negative microorganisms, and β-D-glucan on fungi (Herre *et al.*, 2004). It is now established that β-D-glucan receptors include CR3 (Ross *et al.*, 1987), lactosylceramide (Zimmerman *et al.*, 1998), scavenger receptors (Rice *et al.*, 2002), and Dectin-1 (Brown and Gordon, 2001).

As mentioned above, one of the mechanisms, by which binding of β-D-glucan to the macrophage receptors results in the increased immune protection, is enhancement of the cytokine release. Cytokines are an important contributing factor in immunological and inflammatory reactions. Tumor necrosis factor (TNF) is the major mediator of biophylaxis reaction against Gram-negative bacteria. TNF-α is a cytokine produced mainly by the activated macrophages and shows an array of antibacterial, antiviral, and tumoricidal activities (Havell, 1989; Watanabe and Niitsu, 1991). Previously it has been demonstrated that some β-D-glucans can induce the release of TNF-α from macrophages *in vivo* and *in vitro* (Abel and Czop, 1992; Adachi *et al.*, 1994). However, most of the investigated glucans enhanced TNF-α production stimulated with LPS (priming effect), but did not directly induce TNF-α release (Ohno *et al.*, 1995; Tokunaka *et al.*, 2000). All β-D-glucans tested for stimulation of TNF-α release from macrophages were non-derivatized sometimes semi-soluble samples (Tabata *et al.*, 1981; Maeda *et al.*, 1988) and the conclusion has been made that native triple helical conformation is required for the most effective immunological stimulation (Hirata *et al.*, 1998). Oxidation of neutral β-D-glucans (introduction of carboxy groups) led to destruction of the ordered helical conformation and loss of macrophage-stimulating activity (Tokunaka *et al.*, 2000).

In contrast to these data, our observations revealed that CM-G exerted a potent macrophage-

Table I. Stimulation of release of TNF-α by carboxymethyl glucan (CM-G), carboxymethyl chitin-glucan (CM-CG), and carboxymethyl chitin (CM-C) in three concentrations: 12.5 μg/ml, 25.0 μg/ml, and 50.0 μg/ml. Data are expressed as mean ± SD from at least three independent experiments analyzed by ANOVA and Benferroni's pair-wise tests.

Concentration of stimulant [μg/ml]	TNF-α release [pg/ml]		
	3 h	6 h	24 h
CM-G			
12.5	1390.4 ± 56.6[*]	1322.8 ± 56.4[*]	1145.2 ± 64.9[*]
25.0	1929.0 ± 136.1[*]	1585.4 ± 69.4[*]	1328.1 ± 84.1[*]
50.0	2653.8 ± 42.6[*]	2504.9 ± 63.1[*]	2114.9 ± 108.6[*]
CM-CG			
12.5	34.5 ± 10.8	22.0 ± 6.6	16.4 ± 2.0
25.0	113.9 ± 17.9	90.0 ± 9.7	73.7 ± 7.8
50.0	216.8 ± 13.9[**]	175.8 ± 17.7[**]	160.9 ± 12.9[**]
CM-C			
12.5	13.5 ± 1.8	7.2 ± 1.8	6.4 ± 1.6
25.0	8.11 ± 4.3	6.7 ± 1.6	7.8 ± 3.0
50.0	13.3 ± 2.2	6.3 ± 1.5	5.4 ± 1.1
Non-stimulated cells	9.5 ± 3.8	12.1 ± 4.4	9.0 ± 2.8

[*] $P < 0.001$ was calculated vs. non-stimulated cells (control) and vs. experiments involving CM-CG and CM-C.
[**] $P < 0.001$ was calculated vs. control.

stimulating effect resulting in a dramatic increase of the released TNF-α in comparison to the control (Table I). The eliciting effect was concentration- and time-dependent, increasing (although not proportionally) with the increased concentration of the applied polysaccharide and declining with the prolongation of the cultivation period (Table I). The eliciting effect of CM-CG was much less pronounced, however time- and concentration-dependence patterns were similar to those observed at the application of CM-G. The observed significant diminishment in the stimulation of TNF-α release was due to the presence of chitin component in the chitin-glucan complex. In agreement with this assumption, CM-C revealed almost no stimulating activity on TNF-α release, and the observed values were very close to that of the control. There is no data in the literature reporting cytokine eliciting activity of chitin, the second skeletal polysaccharide of the fungal cell walls. Recently, Feng et al. (2004) reported in vitro stimulation of TNF-α and interleukin-1β release from macrophages elicited by application of oligochitosan – de-N-acetylated derivatives of chitin with low degree of polymerization. However, contrary to β-D-glucan that binds to several glucan-specific receptors, the authors claimed that oligochitosan was bound with a macrophage lectin receptor with D-mannose specificity. Thus, contrary to the macrophage-stimulatory function observed for oligochitosan and high-molecular-weight chitosan (Peluso et al., 1994), we did not observe similar activity by a soluble derivative of chitin and, moreover, presence of chitin in the fungal chitin-glucan complex led to a significant reduction of the activity of the major immunostimulating polysaccharide β-D-glucan. Our observations indicate that the antitumor effect reported by some authors for chitin or chitooligosaccharides (Suzuki et al., 1987; Saiki et al., 1990) should be attributed to other mechanisms than macrophage activation and increased cytokine release.

The documented ability of β-D-glucan to significantly stimulate TNF-α release and the observed differences in the physiological activity of the two fungal polysaccharides open new possibilities for the study of the mechanism of signal transduction in the model systems including mammalian and insect organisms.

Abel G. and Czop J. K. (1992), Stimulation of human monocyte β-glucan receptors by glucan particles induces production of TNF-α and IL-1β. Int. J. Immunopharmacol. **14**, 1363–1373.

Adachi Y., Okazaki M., Ohno N., and Yadomae T. (1994), Enhancement of cytokine production of macrophages stimulated with (1→3)-β-D-glucan, Grifolan (GRN) isolated from *Grifola frondosa*. Biol. Pharm. Bull. **17**, 1554–1560.

Babincová M., Machová E., and Kogan G. (1999), Carboxymethylated glucan inhibits lipid peroxidation in liposomes. Z. Naturforsch. **54c**, 1084–1088.

Babineau T. J., Hackford A., Kenler A., Bistrian B., Forse R. A., Fairchild P. G., Heard S., Keroack M., Caushaj P., and Benotti P. (1994), A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch. Surg. **129**, 1204–1210.

Bartnicki-Garcia S. (1968), Cell wall chemistry, morphogenesis, and taxonomy of fungi. Annu. Rev. Microbiol. **22**, 87–108.

Bohn J. A. and BeMiller J. N. (1995), (1→3)-β-D-Glucans as biological response modifiers: a review of structure-functional activity relationships. Carbohydr. Polym. **28**, 3–14.

Browder W., Williams D., Pretus H., Olivero G., Enrichens F., Mao P., and Franchello A. (1990), Beneficial effect of enhanced macrophage function in trauma patient. Ann. Surg. **211**, 605–613.

Brown G. D. and Gordon S. (2001), Immune recognition: a new receptor for beta-glucans. Nature **413**, 36–37.

Čipák L'., Miadoková E., Dingová H., Kogan G., Novotný L., and Rauko P. (2001), Comparative DNA-protectivity and anti-mutagenity studies using the DNA-topology and Ames assays. Toxicol. *In Vitro* **15**, 677–681.

Czop J. K. and Austen K. F. (1985), Beta-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J. Immunol. **134**, 2588–2593.

Farkaš V. (1979), Biosynthesis of cell walls of fungi. Microbiol. Rev. **43**, 117–144.

Feng J., Zhao L., and Yu Q. (2004), Receptor-mediated stimulatory effect of oligochitosan in macrophages. Biochem. Biophys. Res. Commun. **317**, 414–420.

Goldman R. (1988), Induction of a beta-1,3-D-glucan receptor in P388D1 cells treated with retinoic acid or 1,25-dihydroxyvitamin D$_3$. Immunology **63**, 319–324.

Havell E. A. (1989), Evidence that tumor necrosis factor has an important role in antibacterial resistance. J. Immunol. **143**, 2894–2899.

Herre J., Gordon S., and Brown G. D. (2004), Dectin-1 and its role in the recognition of β-glucans by macrophages. Mol. Immunol. **40**, 869–876.

Hirata N., Tsuzuki A., Ohno N., Saita M., Adachi Y., and Yadomae T. (1998), Cytokine synthesis of human monocytes stimulated by triple or single helical conformer of an antitumour (1→3)-β-D-glucan preparation, sonifilan. Zentralbl. Bakteriol. **288**, 403–413.

Khalikova T. A., Zhanaeva S. Ya., Korolenko T. A., Kaledin V. I., and Kogan G. (2005), Regulation of activity of cathepsins B, L, and D in murine lymphosarcoma model at a combined treatment with cyclophosphamide and yeast polysaccharide. Cancer Lett. **223**, 77–83.

Kogan G. (2000), (1→3,1→6)-β-D-Glucans of yeasts and fungi and their biological activity. In: Studies in Natural Products Chemistry, Vol. 23, Bioactive Natural Products (Part D) (Atta-ur-Rahman, ed.). Elsevier, Amsterdam, pp. 107–152.

Kogan G., Alföldi J., and Masler L. (1988), Carbon-13 NMR spectroscopic investigation of two yeast cell wall β-D-glucans. Biopolymers **27**, 1055–1063.

Kogan G., Masler L., Šandula J., Navarová J., and Trnovec T. (1989), Recent results on the structure and immunomodulating activities of yeast glucan. In: Biomedical and Biotechnological Advances in Industrial Polysaccharides (Crescenzi V., Dea I. C. M., Paoletti S., Stivala S. S., and Sutherland I. W., eds.). Gordon and Breach Science Publishers, New York, pp. 251–258.

Kogan G., Šandula J., Korolenko T. A., Falameeva O. V., Poteryaeva O. N., Zhanaeva S. Ya., Levina O. A., Filatova T. G., and Kaledin, V. I. (2002), Increased efficiency of Lewis lung carcinoma chemotherapy with a macrophage stimulator – yeast carboxymethyl glucan. Int. Immunopharmacol. **2**, 775–781.

Kogan G., Staško A., Bauerová K., Polovka M., Šoltés L., Brezová V., Navarová J., and Mihalová D. (2005), Antioxidant properties of yeast (1→3)-β-D-glucan studied by electron paramagnetic resonance spectroscopy and its activity in the adjuvant arthritis. Carbohydr. Polym. **61**, 18–28.

Machová E., Kogan G., Alföldi J., Šoltés L., and Šandula J. (1995), Enzymatic and ultrasonic depolymerization of carboxymethylated β-1,3-D-glucans derived from *Saccharomyces cerevisiae*. J. Appl. Polym. Sci. **55**, 699–704.

Machová E., Kogan G., Šoltés L., Kvapilová K., and Šandula J. (1999), Ultrasonic depolymerization of the chitin-glucan isolated from *Aspergillus niger*. React. Funct. Polym. **42**, 265–271.

Maeda Y. Y., Watanabe S. T., Chihara C., and Rokutanda M. (1988), Denaturation and renaturation of a beta-1,6;1,3-glucan, lentinan, associated with expression of T-cell-mediated responses. Cancer Res. **48**, 671–675.

Ohno N., Asada N., Adachi Y., and Yadomae T. (1995), Enhancement of LPS triggered TNF-α (Tumor Necrosis Factor-α) production by (1→3)-β-D-glucan in mice. Biol. Pharm. Bull. **18**, 126–133.

Park J. and Rikihisha Y. (1991), Inhibition of *Ehrlichia risticii* infection in murine peritoneal macrophages by gamma interferon, a calcium ionophore and concanavalin A. Infect. Immun. **59**, 3418–3423.

Peluso G., Petillo O., Ranieri M., Santin M., Ambrosio L., Calabro D., Avalone B., and Balsamo G. (1994), Chitosan-mediated stimulation of macrophage function. Biomaterials **15**, 1215–1220.

Pretus H. A., Ensley H. E., McNamee R. B., Jones E. L., Browder I. W., and Williams D. L. (1991), Isolation, physicochemical characterization and preclinical efficacy evaluation of soluble scleroglucan. J. Pharmacol. Exp. Ther. **257**, 500–510.

Rice P. J., Kelley J. L., Kogan G., Ensley H. E., Kalbfleisch J. H., Browder I. W., and Williams D. L. (2002), Human monocyte scavenger receptors are pattern recognition receptors for (1→3)-β-D-glucans. J. Leukocyte Biol. **72**, 140–146.

Ross G. D., Cain J. A., Myones B. L., Newman S. L., and Lachmann P. J. (1987), Specificity of membrane complement receptor type three (CR3) for beta-glucans. Complement **4**, 61–74.

Saiki I., Murata J., Nakajima M., Tokura S., and Azuma I. (1990), Inhibition by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells. Cancer Res. **50**, 3631–3637.

Sakagami Y., Mizoguchi Y., Shin T., Seki S., Kobayashi K., Morisawa S., and Yamamoto S. (1988), Effects of an anti-tumor polysaccharide, schizophyllan, on interferon-gamma and interleukin 2 production by peripheral blood mononuclear cells. Biochem. Biophys. Res. Commun. **155**, 650–655.

Sherwood E. R., Williams D. L., and DiLuzio N. R. (1986), Glucan stimulates production of antitumor cytolytic/cytostatic factor(s) by macrophages. J. Biol. Response Modif. **5**, 504–526.

Sherwood E. R., Williams D. L., McNamee R. B., Jones E. L., Browder I. W., and DiLuzio N. R. (1987), *In vitro* tumoricidal activity of resting and glucan-activated Kupffer cells. J. Leukocyte Biol. **42**, 69–75.

Slameňová D., Lábaj J., Križková L., Kogan G., Šandula, J., Bresgen N., and Eckl P. (2003), Protective effects of fungal (1→3)-β-D-glucan derivatives against oxidative DNA lesions in V79 hamster lung cells. Cancer Lett. **198**, 153–160.

Suzuki K., Mikami T., Okawa Y., Tokoro A., and Suzuki, M. (1987), Antitumor effect of hexa-*N*-acetylchitohexaose and chitohexaose. Carbohydr. Res. **151**, 403–408.

Tabata K., Ito W., Kojima T., Kawabata S., and Misaki, A. (1981), Ultrasonic degradation of schizophyllan, an antitumor polysaccharide produced by *Schizophyllum commune* Fries. Carbohydr. Res. **89**, 121–135.

Thornton B. P., Vetvicka V., Pitman M., Goldman R. C., and Ross G. D. (1996), Analysis of the sugar specificity and molecular location of the β-glucan-binding lectin site of complement receptor type 3 (CD11b/CD18). J. Immunol. **156**, 1235–1246.

Tokunaka K., Ohno N., Adachi Y., Tanaka S., Tamura H., and Yadomae T. (2000), Immunopharmacological and immunotoxicological activities of a water-soluble (1→3)-β-D-glucan, CSBG from *Candida* spp. Int. J. Immunopharmacol. **22**, 383–394.

Vetvicka V., Thornton B. P., and Ross G. D. (1996), Soluble β-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state capable of mediating cytotoxicity of iC3b-opsonized target cells. J. Clin. Invest. **98**, 50–57.

Watanabe N. and Niitsu Y. (1991), Antitumor effect of tumor necrosis factor. Biotherapy **5**, 1634–1643.

Williams D. L. (1997), Overview of (1→3)-β-D-glucan immunobiology. Mediators Inflamm. **6**, 247–250.

Williams J. D., Topley N., Alobaidi H. M., and Harber M. J. (1986), Activation of human polymorphonuclear leukocytes by particular zymosan is related to both its major carbohydrate components: glucan and mannan. Immunology **58**, 117–124.

Williams D. L., Mueller A., and Browder W. (1996), Glucan-based macrophage stimulators. A review of their anti-infective potential. Clin. Immunother. **5**, 392–399.

Zimmerman J. W., Lindermuth J., Fish P. A., Palace G. P., Stevenson T. T., and DeMong D. E. (1998), A novel carbohydrate–glycosphingolipid interaction between a beta-(1–3)-glucan immunomodulator, PGG-glucan, and lactosylceramide of human leukocytes. J. Biol. Chem. **273**, 22014–22020.